CEDAR KNOLLS, N.J.,
April 15, 2020 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and the
owner of Fortetropin®, a proprietary bioactive
composition that helps build lean muscle, announced the publication
of a study that concluded that the use of Fortetropin
decreased muscle atrophy in dogs following tibial-plateau leveling
osteotomy (TPLO).
The study, titled, "Fortetropin inhibits disuse muscle
atrophy in dogs after tibial plateau leveling osteotomy,"
published in the peer-reviewed, open-access scientific journal,
PLOS ONE (Public Library of Science), reports results from a
randomized, double-blind, placebo-controlled study involving 100
dogs conducted by researchers at Kansas State
University College of Veterinary Medicine. The study
can be found here.
TPLO is the most common orthopedic surgery procedure performed
on dogs in the United States.
Dogs undergoing TPLO and other orthopedic procedures are
often subjected to activity restriction, and the development of
disuse muscle atrophy following orthopedic injuries has been well
documented. The study evaluated the use of Fortetropin to
reverse or inhibit disuse muscle atrophy in dogs recovering from
TPLO surgery. The key highlights of the study results
were:
- Dogs that received Fortetropin experienced reduced muscle loss
compared to dogs that received the placebo (p<0.05).
- Dogs that received Fortetropin did not experience increased
myostatin levels in contrast to dogs that received the placebo
(p<0.05) (myostatin is a protein that significantly impedes
the growth and development of new muscle tissue).
- Dogs that received Fortetropin experienced greater improvement
in weight bearing capacity on their operated limb when compared to
dogs that received the placebo (p<0.1).
Kenneth R. Harkin, DVM, DACVIM
(SAIM), Professor and Section Head, College of Veterinary
Medicine, Kansas State University, and principal investigator
of the study, remarked, "This study demonstrates the benefits of
Fortetropin in dogs with prolonged post-operative recovery periods.
Restoration or maintenance of muscle mass through the reduction of
serum myostatin levels with Fortetropin offers veterinarians a
novel approach to in-home rehabilitation of injured dogs, including
potentially improving or restoring mobility in geriatric
dogs. Given that myostatin is the common denominator in
muscle mass loss of various causes, Fortetropin potentially could
also improve or restore mobility in geriatric dogs with muscle mass
loss."
"The results from this peer-reviewed study on the impact that
Fortetropin has on recovery in dogs following TPLO surgery are very
impressive," commented Sherman O. Canapp,
Jr., DVM, MS, CCRT, DACVS, DACVSMR, Co-Founder, Veterinary
Orthopedic Sports Medicine Group, Annapolis Junction, MD, a key expert who was
not involved in the study. "Based on the study results
in this publication, I will definitely be recommending Fortetropin
to my patients following orthopedic procedures."
Joseph Mannello, CEO of MYOS,
commented, "There are extremely few nutrition products available in
the veterinary market that address muscle health and that have
been studied as rigorously as Fortetropin. By investing in
first class research at leading academic institutes, we aspire to
redefine veterinary care for geriatric dogs and dogs recovering
from TPLO. Multiple clinical studies have shown that the risk
of mortality is elevated in dogs that experience muscle loss.
As a result, we believe that the publication of this peer reviewed
study represents a major milestone for MYOS as we look to expand
our animal health business to address a need that has been largely
unmet."
According to an article in Vox, the pet supplement
industry had an estimated value in 2018 of $636 million while the pet food industry is
expected to reach $35 billion by
2024. Based on a survey conducted by the American Pet
Products Associations, 67% of American households owned a pet,
which translates to approximately 84.9 million households in
the United States that include a
pet of some kind.
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness and produces muscle
health support products featuring Fortetropin under the names of
Yolked®, Physician Muscle Health
Formula®, MYOS Canine Muscle
Formula®, (Regular & Vet Strength) and
Qurr®. For more information, please visit
www.myosrens.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including Yolked®, Physician Muscle
Health Formula®, MYOS Canine Muscle Formula®,
Qurr®, and MYOS Enteral
Nutrition Formula™, the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects,
including the results of the clinical study discussed in this
release, the ability to enter into new partnership opportunities
and the success of our existing partnerships, the ability to
generate revenue and cash flow from sales of our products, the
ability to increase our revenue and gross profit margins, the
ability to achieve a sustainable, profitable business, the effect
of economic conditions, the ability to protect our intellectual
property rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, risks from the impact of the coronavirus,
and other factors discussed from time to time in our filings
with the Securities and Exchange Commission. We undertake no
obligation to update or revise any forward-looking statement for
events or circumstances after the date on which such statement is
made except as required by law.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-announces-publication-of-landmark-clinical-study-on-recovery-in-dogs-following-tplo-surgery-301040733.html
SOURCE MYOS RENS Technology